Eli Lilly flags counterfeit Mounjaro seizure in Gurugram

The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.

Pharma firms accelerate regional GLP-1 capacity to de-risk supply chains amid geopolitical tensions: GlobalData

At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy

GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen

GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions

Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes

The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema

The company announced positive topline data from the Phase 3 ADorable-1 trial

Samsung Biologics, Eli Lilly team up to launch major biotech hub in Korea

The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms